Detection of venous thromboembolic diseases by measurement of D-dimers and soluble fibrin levels
View Patent ↗A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.
1. An in vitro method for diagnosing coagulation activation linked to a risk of thromboembolic disease starting from a blood sample removed from a patient, comprising:
i) measuring a quantity of fibrin degradation products contained in the sample, by measuring a quantity of D-dimers present in the sample and constituting a base level of D-dimers;
ii) treating the sample by incubation with a plasminogen activator with a high affinity for fibrin (Pa-Fb sp) under conditions allowing degradation of soluble fibrin contained in the sample into degradation products without resulting in degradation of fibrinogen, and measuring a quantity of D-dimers contained in the treated sample;
iii) calculating a difference between the quantity of D-dimers measured after activation by the Pa-Fb sp activator in step ii) and the quantity of D-dimers before said activation measured in step i), said difference constituting a degree of degradation of soluble fibrin (SDF);
iv) comparing the level of D-dimers measured in step i) with a normal threshold value determined for said degradation product and comparing the level of SDF calculated in step iii) with a normal threshold value determined for SDF;
a risk of thromboembolic disease existing if at least one of the levels of D-dimers measured in step i) or the calculated level of SDF obtained in step iii) is higher than the respective determined normal value and said risk being excluded when the level of D-dimers obtained in step i) and the level of SDF obtained in step iii) are lower than the respective normal threshold values.
2. The method according to claim 1 , for investigating a thromboembolic venous disease.
3. The method according to claim 1 , applied to investigating venous thrombus formation.
4. The method according to claim 1 , for the diagnosis of a deep venous thrombosis.
5. The method according to claim 1 , for the diagnosis of a pulmonary embolism.
6. The method according to claim 1 , wherein the blood sample is a plasma sample.
7. The method according to claim 1 , wherein the blood sample is that of a patient benefiting from an anti-coagulation therapy.
8. The method according to claim 5 , wherein the Pa-Fb sp plasminogen activator is t-PA.
9. The method according to claim 1 , wherein fibrinogen degradation is prevented by adding a plasmin inhibitor.
10. The method according to claim 9 , wherein the plasmin inhibitor is aprotinin, which is added after incubating the sample for 15 minutes at 37° C. with the Pa-Fb plasminogen activator.
11. The method according to claim 1 , wherein prior to incubation of the sample with the Pa-Fb plasminogen activator, an anti-coagulant is added to the sample.
12. The method according to claim 1 , further comprising assaying the degradation products of soluble fibrin in a negative control sample and in a positive control sample.
13. The method according to claim 1 , wherein the D-dimers are measured using anti-D-dimer monoclonal antibody.
14. The method according to claim 1 , further comprising measuring the SDF present in a positive control sample constituted by a normal plasma sample by carrying out steps comprising:
i) incubating a plasma sample with a coagulation activator to allow the formation of soluble fibrin without forming a fibrin clot;
ii) incubating the treated sample with a coagulation inhibitor in a quantity sufficient to block coagulation,
iii) bringing the prepared sample comprising soluble fibrin monomers into contact with a plasminogen activator with a high affinity for fibrin (Pa-Fb sp) under conditions allowing degradation of the soluble fibrin contained in the sample into its degradation products, especially D-dimers, without degrading the fibrinogen.
15. The method according to claim 1 , wherein the normal threshold value for the quantity of D-dimers is 500 ng/ml and the normal threshold value for SDF is 300 ng/ml, a diagnosis excluding thromboembolic disease being made when the measured values of the test sample are less than the two respective threshold values.
16. A kit for diagnosing thromboembolic disease using a method according to claim 1 , comprising:
anti D-dimer monoclonal antibodies;
a plasminogen activator with a high specificity for fibrin (Pa-Fb sp);
a plasmin inhibitor; and
a positive control sample for soluble fibrin and if appropriate a negative control sample.
17. The method according to claim 14 , wherein the coagulation activator is a small quantity of thrombin to induce the formation of soluble fibrin.
18. The method according to claim 14 , wherein the plasminogen activator with a high affinity for fibrin (Pa-Fb sp) is t-PA.
19. The method of according to claim 11 , wherein the anti-coagulant comprises citric acid and trisodium citrate.
20. The method of according to claim 14 , wherein the coagulation inhibitor is heparin or hirudin.